In this EP Edge™ Journal Watch Breaking News Special Edition, Dr. Niraj Sharma delivers an in-depth analysis of the CHAMPION-AF trial and places its findings in direct comparative context with PRAGUE-17 and CLOSURE-AF, three pivotal randomized studies shaping the modern debate around left atrial appendage closure (LAAC/LAAO) versus direct oral anticoagulants (DOACs) for stroke prevention in atrial fibrillation.
This episode goes well beyond a simple trial summary. It examines whether percutaneous left atrial appendage closure can truly challenge contemporary DOAC-first management in patients with nonvalvular atrial fibrillation, and whether the latest evidence justifies broader expansion of LAAC in routine electrophysiology practice. The discussion focuses on the real clinical questions facing electrophysiologists, cardiologists, and stroke prevention specialists in 2026: Which patients remain best served by oral anticoagulation? Where does LAAC still have a meaningful role? And how should clinicians interpret noninferiority claims when ischemic events, bleeding definitions, and procedural risk tell a more complicated story?
The episode begins with a detailed breakdown of CHAMPION-AF, including trial design, patient selection, baseline stroke and bleeding risk, endpoint construction, and the interpretation of the primary efficacy and safety results. Particular attention is given to the noninferiority framework, the absolute margin used in the study, the numerical ischemic stroke signal in the device arm, the distinction between procedure-related and non–procedure-related bleeding, and the critical question of whether the reported bleeding advantage is robust enough to offset the upfront risk of device implantation. The discussion also explores why the lack of drug-specific DOAC breakdown matters when interpreting a comparator arm labeled broadly as “NOAC therapy.”
The episode then turns to PRAGUE-17, a landmark randomized comparison of LAAC versus DOAC therapy in high-risk atrial fibrillation patients, and explains why it remains one of the strongest supportive trials for selective LAAC use. Dr. Sharma reviews the long-term follow-up, the late divergence in nonprocedural bleeding, the importance of the apixaban-dominant comparator arm, and why PRAGUE-17 supports careful patient selection rather than routine substitution of LAAC for anticoagulation.
The analysis then addresses CLOSURE-AF, a major counterweight in this space and arguably one of the most clinically relevant studies for real-world decision-making. In an older, frailer, higher-risk atrial fibrillation cohort, CLOSURE-AF did not establish a compelling advantage for LAAC over medical therapy. This episode explains why that matters, how procedural risk and early harm affect interpretation, and why CLOSURE-AF materially raises the evidentiary bar for any effort to expand LAAC indications.
Across all three trials, this EP Edge™ Journal Watch special edition provides a true comparative analysis of CHAMPION-AF, PRAGUE-17, and CLOSURE-AF, highlighting differences in population risk, device strategy, endpoint design, bleeding definitions, ischemic outcomes, and external validity. The goal is not simply to ask whether LAAC “works,” but to determine where LAAC fits in the actual clinical flow of contemporary atrial fibrillation care.
This episode is ideal for listeners seeking a high-level, clinically grounded discussion of atrial fibrillation stroke prevention, Watchman FLX, left atrial appendage occlusion, LAAC versus DOACs, noninferiority trial interpretation, bleeding risk, ischemic stroke outcomes, and evidence-based patient selection in electrophysiology practice.
For electrophysiologists, cardiologists, fellows, APPs, and clinicians following the evolving literature on CHAMPION-AF, PRAGUE-17, and CLOSURE-AF, this special edition offers a nuanced, data-driven perspective on one of the most important current controversies in heart rhythm medicine.
Portugal